Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain

Table 1

Previous brain SNCA expression studies.

Study	Method	Brain Region	#Samples (PD/C)	PMI, hours (range)^1	Expression in PD compared to controls	SNCA Transcript
Neystat et al. (1999) [7]	Ribonuclease protection assay	Substantia nigra	15 (9/6)	11.55 (4–18); 10.62 (3.5–17)	Decreased, both transcripts	NM_000345.2; NM_007308.1
		Frontal cortex	15 (9/6)	11.55 (4–18); 10.62 (3.5–17)	No significant difference
Kingsbury et al. (2004) [9]	Semiquantitative in situ	Substantia nigra	11 (7/4)	23.2 (9.3–56); 33.0 (22–53)	Decreased	NM_000345.2
	Hybridization	Frontal cortex	12 (8/4)	24.4 (10.6–40); 33.0 (22–53)	Decreased
		Temporal cortex	12 (8/4)	24.4 (10.6–40); 33.0 (22–53)	No significant difference
Chiba-Falek et al. (2006) [11]	Real-time PCR	Mid-brain	14 (7/7)	16.93 (2.00–22.08); 18.62 (14–24)	Increased	NM_000345.2
		Frontal cortex	7 (4/3)	14 (2–20); 24.66 (22–28)	No significant difference
Fuchs et al. (2008) [13]	Real-time PCR	Substantia nigra	22 (8/14)	All: 25 (N/A)	No significant difference	NM_000345.2
		Cingulate gyrus	32 (13/19)	All: 22 (N/A)	No significant difference
		Cerebellum	10 (5/5)	All: 15 (N/A)	Decreased
Beyer et al. (2011) [14]	Real-time PCR	Caudate nucleus	21 (7/14)	6.03 (3.5–7.0); 7.40 (3.5–13.0)	No significant difference	NM_007308.1
		Pons	21 (7/14)	6.03 (3.5–7.0); 7.40 (3.5–13.0)	No significant difference
		Temporal cortex	21 (7/14)	6.03 (3.5–7.0); 7.40 (3.5–13.0)	No significant difference

C: Control; PD: Parkinson disease.
NM_000345.2 =140 amino acid isoform; NM_007308.1 =112 amino acid isoform.
¹The postmortem interval mean and range data for PD samples are on the first line and those for control samples are on the second line. The Fuchs et al. study (2008) only had aggregate mean postmortem interval data available.